ABMC American Bio Medica Corporation (CE)

American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three and six months ended June 30, 2013.

Net sales for the second quarter of 2013 were $2,380,000, compared to $2,462,000 in the second quarter of 2012, representing a decrease of $82,000, or 3.3%. For the six months ended June 30, 2013, net sales were $4,505,000 compared to $4,758,000 for the six months ended June 30, 2012, representing a decrease of $253,000, or 5.3%.

The Company reported an operating loss of $(211,000) in the second quarter of 2013, compared to an operating loss of $(30,000) in the second quarter of 2012. Net loss for the second quarter of 2013 was $(294,000), or $(0.01) per share, compared to a net loss of $(77,000), or $(0.00) per share in the second quarter of 2012. Operating loss for the first six months of 2013 was $(573,000), compared to an operating loss of $(199,000) in the first six months of 2012. Net loss for the first half of 2013 was $(718,000), or $(0.03) per share, compared to a net loss of $(283,000), or $(0.01) per share in the first half of 2012.

ABMC Chief Executive Officer Stan Cipkowski stated, "Sales growth in our core markets continues to be elusive, not only for ABMC but for our entire industry. This continues to be for the same reasons that have plagued us for the past several years, high unemployment and the uncertain worldwide economic outlook. With the introduction of two new products, pending FDA clearance, we expect to see sales and earnings growth in new and expanded markets in the near future."

Cipkowski continued, "Gross margins have returned to appropriate historical levels, and though we have continued to cut operating expenses, costs related to regulatory clearance for the new products as well as costs associated with additional funding caused increased G&A expenses. Diversification continues to be our primary objective in 2013."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2012, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

  AMERICAN BIO MEDICA CORPORATION Condensed Statements of Operations (unaudited)           For the three For the three For the six For the six months ended months ended months ended months ended   June 30, 2013     June 30, 2012     June 30, 2013     June 30, 2012   Net sales $ 2,380,000 $ 2,462,000 $ 4,505,000 $ 4,758,000 Cost of goods sold   1,411,000       1,420,000       2,750,000       2,753,000   Gross profit   969,000       1,042,000       1,755,000       2,005,000     Operating expenses: Research and development 115,000 55,000 178,000 108,000 Selling and marketing 491,000 529,000 966,000 1,050,000 General and administrative   574,000       488,000       1,184,000       1,046,000   Total operating expenses   1,180,000       1,072,000       2,328,000       2,204,000     Operating loss   (211,000 )     (30,000 )     (573,000 )     (199,000 )   Other expense   (82,000 )     (44,000 )     (143,000 )     (86,000 )   Net loss before tax (293,000 ) (74,000 ) (716,000 ) (285,000 )   Income tax (expense) / benefit   (1,000 )     (3,000 )     (2,000 )     2,000     Net loss $ (294,000 )   $ (77,000 )   $ (718,000 )   $ (283,000 )   Basic & diluted (loss) / income per common share

$

(0.01

)

 

$

(0.00

)

 

$

(0.03

)

 

$

(0.01

)

  Weighted average shares outstanding – basic and diluted  

22,166,336

     

21,744,768

     

22,109,560

     

21,744,768

   

  American Bio Medica Corporation Condensed Balance Sheets     June 30, December 31,  

2013(unaudited)

    2012   ASSETS Current Assets Cash and cash equivalents $ 55,000 $ 89,000 Accounts receivable, net of allowance for doubtful accounts of $59,000 at June 30, 2013 and $60,000 at December 31, 2012

1,054,000

810,000

Inventory, net of allowance for slow moving and obsolete inventory of $358,000 at June 30, 2013 and $261,000 at December 31, 2012

2,481,000

2,571,000

Prepaid expenses and other current assets   103,000       50,000   Total current assets 3,693,000 3,520,000 Property, plant and equipment, net 1,190,000 1,192,000 Debt issuance costs, net 346,000 29,000 Patents 23,000 24,000 Other assets   14,000       14,000   Total assets $ 5,266,000     $ 4,779,000     LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable 648,000 $ 1,016,000 Accrued expenses and other current liabilities 215,000 174,000 Wages payable 239,000 231,000 Line of credit 1,583,000 321,000 Current portion of long-term debt   1,318,000       1,404,000   Total current liabilities 4,003,000 3,146,000 Other liabilities 146,000 145,000 Related party note   124,000       124,000   Total liabilities 4,273,000 3,415,000   COMMITMENTS AND CONTINGENCIES Stockholders’ Equity: Common stock 222,000 218,000 Additional paid-in capital 19,833,000 19,490,000 Accumulated deficit   (19,062,000 )     (18,344,000 ) Total stockholders’ equity   993,000       1,364,000   Total liabilities and stockholders’ equity $ 5,266,000     $ 4,779,000